Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 188

Sort by

Sort Order Select

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Blood (2024) 144 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2024-207230

Published: 2024

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Paul J. Bröckelmann, Ina Bühnen, Josée M Zijlstra, Stephan Mathas, Katrin S Roth, Maria Garcia-Marquez, Christian Sillaber, Julia Meissner, Alexander Fossa, Richard Greil, Karolin Trautmann-Grill, Johannes Rosenbrock, Wouter Plattel, Hans A Schlösser, Carsten Kobe, Michael Fuchs, Peter Borchmann, Christian Baues

Blood (2024) 144 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2024-202113

Published: 2024

Journal Articles

Using Different Vaf Cut-Offs, Myeloid NGS Analysis of 924 Paired Peripheral Blood/Bone Marrow Samples Yielding 6944 Result Pairs Reveal Peripheral Blood As Safe Alternative Sample to Bone Marrow, Irrespective of the Degree of Neutropenia or Circulating Blast Counts

Lisa Pleyer, Manuel Drost, Jakob Wagner, Bettina Jansko-Gadermeir, Franz F Gassner, Nadja Zaborsky, Thomas Dillinger, Sonja Hutter, Viktoria Faber, Thomas Melchardt, Richard Greil

Blood (2024) 144 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2024-209613

Published: 2024

Journal Articles

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Blood (2024) 144 (Supplement 1): 7511.

https://doi.org/10.1182/blood-2024-208073

Published: 2024

Journal Articles

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Inga M. Schimansky, Andreas Tiede, Christiane Dobbelstein, Dr. Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul N. Knöbl, Johannes Oldenburg, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Moehnle, Katharina Holstein, Wolfgang A. Miesbach

Blood (2024) 144 (Supplement 1): 555.

https://doi.org/10.1182/blood-2024-205490

Published: 2024

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

CD49d Shapes B Cell Receptor Responsiveness and Tissue Distribution in an Aggressive Chronic Lymphocytic Leukemia Murine Model

Blood (2023) 142 (Supplement 1): 81.

https://doi.org/10.1182/blood-2023-179726

Published: 2023

Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy

Blood (2023) 142 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2023-188854

Published: 2023

Journal Articles

Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib

Alexander Pichler, Christoph Kornauth, Ines Garces De Los Fayos Alonso, Lukas Kazianka, Arne Zibat, Luca Mologni, Halima Alachram, Tea Pemovska, Gerwin Heller, Richard Greil, Lukas Kenner, Ulrich Jaeger, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 1691.

https://doi.org/10.1182/blood-2023-188835

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Lukas Kazianka, Tea Pemovska, Johannes Rohrbeck, Christoph Kornauth, Alexander Pichler, Christiane Agreiter, Simone Lubowitzki, Katharina Prochazka, Peter Neumeister, Clemens Schmitt, Richard Greil, Wolfgang Willenbacher, Dominik Wolf, Ulrich Jaeger, Ingrid Simonitsch-Klupp, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2023-189856

Published: 2023

Journal Articles

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Christina Hart, Robert Klamroth, Ulrich J. Sachs, Richard Greil, Paul N. Knoebl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Isabell Pekrul, Katharina Holstein, Hermann Eichler, Carmen Weigt, Dorothea Schipp, Sonja Werwitzke, Andreas Tiede

Blood (2023) 142 (Supplement 1): 2612.

https://doi.org/10.1182/blood-2023-174958

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Dennis A. Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M. Zijlstra, Bernd Hertenstein, Max S. Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann

Blood (2023) 142 (6): 553–560.

https://doi.org/10.1182/blood.2023019939

Published: 2023

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Felix Keil, Antonia Maria Susanne Müller, Andrea Berghold, Veronika Buxhofer-Ausch, Judith Schuster, Regina Riedl, Corinne Vorburger, Alexandra Boehm, Michael Panny, Thomas Noesslinger, Richard Greil, Panagiotis Samaras, Thomas Pabst

Blood (2022) 140 (Supplement 1): 1180–1182.

https://doi.org/10.1182/blood-2022-157917

Published: 2022

Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2010–2013.

https://doi.org/10.1182/blood-2022-166084

Published: 2022

NARROW

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Using Different Vaf Cut-Offs, Myeloid NGS Analysis of 924 Paired Peripheral Blood/Bone Marrow Samples Yielding 6944 Result Pairs Reveal Peripheral Blood As Safe Alternative Sample to Bone Marrow, Irrespective of the Degree of Neutropenia or Circulating Blast Counts

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

CD49d Shapes B Cell Receptor Responsiveness and Tissue Distribution in an Aggressive Chronic Lymphocytic Leukemia Murine Model

Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only